Jesper Pallesen
Immunology and Microbiology · Indiana University
Publications
73
Citations
5,041
Est. group size
—
Recurring co-author estimate
Active years
18
Publishing since 2009
Jesper Pallesen studies how the immune system recognizes viruses and how vaccines and antibody-based therapies can be designed to fight infections such as HIV, SARS-CoV-2 (the virus that causes COVID-19), and malaria. The work combines structural biology (mapping the detailed 3D shapes of viral proteins and antibodies), computational protein design, and experimental testing in animals and early human trials. A recurring focus is engineering antibodies and delivering them or the instructions to make them (for example via DNA) to protect against disease.
After a peak around 2018 and a dip in 2020-2023, publication activity has grown again over the last two years, averaging about 4 papers per year over the past five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates
Nature Immunology · 2026
- Deep mining of the human antibody repertoire identifies frequent and genetically diverse CDRH3 topologies targetable by vaccination
Proceedings of the National Academy of Sciences · 2026
- 661. Phase 1, dose-escalation trial of the safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies (DMAb) in healthy adults
Open Forum Infectious Diseases · 2026
- Conformational landscape of HIV-1 Env from closed to fully open
Nature Communications · 2026
- Engineering single-dose plasmid DNA for sustained in vivo delivery of designer incretins
Trends in biotechnology · 2026
- Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants
Research Square · 2026
- Generation and MHC class II loading of an endogenous influenza epitope revealed by a T cell receptor-like antibody
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial
Nature Medicine · 2025
- Phase 1, dose-escalation trial of the safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies (DMAb) in healthy adults
Research Square · 2025
- Machine learning enables <i>de novo</i> multi-epitope design of plasmodium falciparum circumsporozoite protein to target trimeric L9 antibody
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Rapid elicitation of a new class of neutralizing N332-glycan independent V3-glycan antibodies against HIV-1 in nonhuman primates
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Machine learning enables de novo multiepitope design of <i>Plasmodium falciparum</i> circumsporozoite protein to target trimeric L9 antibody
Proceedings of the National Academy of Sciences · 2025
- Conformational Landscape of HIV-1 Env from Closed to Fully Open
Research Square · 2025
- Growing Glycans in Rosetta: Accurate de novo glycan modeling, density fitting, and rational sequon design
PLoS Computational Biology · 2024
- Deep Mining of the Human Antibody Repertoire Identifies Frequent and Genetically Diverse CDRH3 Topologies Targetable by Vaccination
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- bioRxiv (Cold Spring Harbor Laboratory)×11
- Cell Reports×4
- Nature Communications×4
- Research Square×4
- Proceedings of the National Academy of Sciences×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile